Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria

Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria

Adverse drug reaction (ADR), commonly termed as unwanted reaction is a longstanding and a major medical problem that comes with many clinically important drugs. ADRs are broadly categorized into predictable (type A) and unpredictable (type B) reactions. Predictable reaction is usually dose dependent...

Full description

Saved in:
Bibliographic Details
Main Author: Zakaria, Hasbullani
Format: Thesis
Language:English
Published: 2014
Online Access:https://ir.uitm.edu.my/id/eprint/17478/2/TM_HASBULLANI%20ZAKARIA%20PH%2014_5.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
id my-uitm-ir.17478
record_format uketd_dc
spelling my-uitm-ir.174782022-03-01T02:46:47Z Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria 2014 Zakaria, Hasbullani Adverse drug reaction (ADR), commonly termed as unwanted reaction is a longstanding and a major medical problem that comes with many clinically important drugs. ADRs are broadly categorized into predictable (type A) and unpredictable (type B) reactions. Predictable reaction is usually dose dependent, related to the known pharmacologic actions of drugs, and occurs in healthy individuals. Unpredictable reactions are generally dose independent, are not related to the pharmacologic actions of drugs, and only occur in susceptible individuals. Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are two fatal ADR encountered in some patients prescribed carbamazepine or phenytoin. US FDA had published a medical alert with a recommendation of HLA-B*1502 screening before these two (2) drugs were prescribed to patients with Asian ancestry as the likelihood of SJS/TEN were highly associated with HLA-B*1502. For the methods, eighty (80) healthy unrelated individuals and eighty six (86) patients attending clinics at Department of Neurology of a local hospital were recruited. DNA was extracted from blood samples obtained from each patient. HLA-B*1502 genotype was determined by AS-PCR developed in house. All statistical analysis was performed using SPSS software version 20. P values < 0.05 were considered statistically significant. The strength of association between HLA-B*1502 with CBZ-induced SJS-TEN was estimated by calculating the odd ratio. For the results, among the 86 patients, 40 were newly registered patients and genotype screening was conducted before patients were prescribed with CBZ. Among this group, 17.5% were positive for HLA-B*1502. In another cohort in which CBZ had been withdrawn due to SJS/ TEN; all of them (15) were positive for HLAB* 1502. One patient with positive HLA-B*1502 however did not develop SJS/TEN and is therefore tolerant. The frequency of HLA-B*1502 allele in CBZ-SJS/TEN after CBZ prescribed was 32.6%. The calculated ratio of patients at risk of developing SJS/TEN based on this small samples size is 120.2727 (95% CI: 6.1202 - 2363.5775; p = 0.0016). For the conclusion, the screening of patients for the HLA-B*1502 allele before the initiation of carbamazepine treatment and withholding carbamazepine from HLA-B*1502-positive patients can reduce the incidence of carbamazepine-induced SJS-TEN among the Malaysia. This study conclude that the implementation of HLAB* 1502 screening is necessary to avoid patients at risk of SJS/TEN from being prescribed CBZ due to the high odd ratio observed in this study. 2014 Thesis https://ir.uitm.edu.my/id/eprint/17478/ https://ir.uitm.edu.my/id/eprint/17478/2/TM_HASBULLANI%20ZAKARIA%20PH%2014_5.pdf text en public mphil masters Universiti Teknologi MARA Faculty of Pharmacy
institution Universiti Teknologi MARA
collection UiTM Institutional Repository
language English
description Adverse drug reaction (ADR), commonly termed as unwanted reaction is a longstanding and a major medical problem that comes with many clinically important drugs. ADRs are broadly categorized into predictable (type A) and unpredictable (type B) reactions. Predictable reaction is usually dose dependent, related to the known pharmacologic actions of drugs, and occurs in healthy individuals. Unpredictable reactions are generally dose independent, are not related to the pharmacologic actions of drugs, and only occur in susceptible individuals. Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are two fatal ADR encountered in some patients prescribed carbamazepine or phenytoin. US FDA had published a medical alert with a recommendation of HLA-B*1502 screening before these two (2) drugs were prescribed to patients with Asian ancestry as the likelihood of SJS/TEN were highly associated with HLA-B*1502. For the methods, eighty (80) healthy unrelated individuals and eighty six (86) patients attending clinics at Department of Neurology of a local hospital were recruited. DNA was extracted from blood samples obtained from each patient. HLA-B*1502 genotype was determined by AS-PCR developed in house. All statistical analysis was performed using SPSS software version 20. P values < 0.05 were considered statistically significant. The strength of association between HLA-B*1502 with CBZ-induced SJS-TEN was estimated by calculating the odd ratio. For the results, among the 86 patients, 40 were newly registered patients and genotype screening was conducted before patients were prescribed with CBZ. Among this group, 17.5% were positive for HLA-B*1502. In another cohort in which CBZ had been withdrawn due to SJS/ TEN; all of them (15) were positive for HLAB* 1502. One patient with positive HLA-B*1502 however did not develop SJS/TEN and is therefore tolerant. The frequency of HLA-B*1502 allele in CBZ-SJS/TEN after CBZ prescribed was 32.6%. The calculated ratio of patients at risk of developing SJS/TEN based on this small samples size is 120.2727 (95% CI: 6.1202 - 2363.5775; p = 0.0016). For the conclusion, the screening of patients for the HLA-B*1502 allele before the initiation of carbamazepine treatment and withholding carbamazepine from HLA-B*1502-positive patients can reduce the incidence of carbamazepine-induced SJS-TEN among the Malaysia. This study conclude that the implementation of HLAB* 1502 screening is necessary to avoid patients at risk of SJS/TEN from being prescribed CBZ due to the high odd ratio observed in this study.
format Thesis
qualification_name Master of Philosophy (M.Phil.)
qualification_level Master's degree
author Zakaria, Hasbullani
spellingShingle Zakaria, Hasbullani
Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria
author_facet Zakaria, Hasbullani
author_sort Zakaria, Hasbullani
title Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria
title_short Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria
title_full Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria
title_fullStr Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria
title_full_unstemmed Relevance of genetic polymorphism of HLA-B*1502 in carbamazepine-induced cutaneous adverse drug reactions / Hasbullani Zakaria
title_sort relevance of genetic polymorphism of hla-b*1502 in carbamazepine-induced cutaneous adverse drug reactions / hasbullani zakaria
granting_institution Universiti Teknologi MARA
granting_department Faculty of Pharmacy
publishDate 2014
url https://ir.uitm.edu.my/id/eprint/17478/2/TM_HASBULLANI%20ZAKARIA%20PH%2014_5.pdf
_version_ 1783733562574372864

Similar Items